Condition: Metastatic Squamous Non-Small Cell Lung Carcinoma · Sponsor: University of Illinois at Chicago
This is a phase II study to assess the efficacy, safety, and Health Related Quality of Life (HRQoL) of combination cabozantinib and pembrolizumab as maintenance therapy for patients with metastatic squamous Non Small Cell Lung Cancer(sqNSCLC) who have received 4 cycles of induction therapy with pembrolizumab, carboplatin, and nab-paclitaxel or paclitaxel.
This description comes directly from the study's public registry record.
Ryan Nguyen, DO · 312-996-1581 · rnguye8@uic.edu
Ruihong Yin, BSN · 312-355-2545 · ryin6@uic.edu
Always discuss trial participation with your own doctor first.
| Ryan Nguyen | Chicago, Illinois, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05613413